This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy cand...
Human medicines European public assessment report (EPAR): Kavigale, sipavibart, ...
The company said its approach has helped cut the number of discarded livers in h...
Looking to avoid a repeat of the shortages that plagued Mounjaro and Zepbound du...
The company said its U.S. rollout represents the largest-ever commercial launch ...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
An approval for the first drug for a rare lipid storage disease, some FDA worker...
Revenues in the biopharma industry continued to boom in the fourth quarter of la...
Revenues in the biopharma industry continued to boom in the fourth quarter of la...
The Pfizer CEO at the White House, CDC vaccine efforts, and other crucial biotec...
In today's Morning Rounds newsletter, a viral vaccine study, rehired FDA employe...
Patrizia Cavazzoni, formerly the top regulator of the drug division of the FDA, ...
If the Trump administration truly wants to reduce waste and fraud in government ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the indus...
As OS Therapies prepares to take its bacteria-based cancer asset to the FDA for ...
New Approach Methodologies EU-IN Horizon Scanning Report
The Trump administration has started quietly rehiring some of the FDA employees ...
Agenda of the CHMP meeting 24-27 February 2025
Annex to 24-27 February 2025 CHMP Agenda
Hear from UCB’s Brad Chapman on the importance of inclusion, representation, and...
Sanofi has shared a deeper dive into its 469 million euro bowel disease bet, pub...
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluti...
Human medicines European public assessment report (EPAR): Relvar Ellipta, flutic...
Avoid common pitfalls in EU orphan drug market access—learn how local expertise ...